首页 | 本学科首页   官方微博 | 高级检索  
     


Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label,single-arm,multicentre, phase 2 study
Authors:Arjun V Balar  Ashish M Kamat  Girish S Kulkarni  Edward M Uchio  Joost L Boormans  Mathieu Roumiguié  Laurence E M Krieger  Eric A Singer  Dean F Bajorin  Petros Grivas  Ho Kyung Seo  Hiroyuki Nishiyama  Badrinath R Konety  Haojie Li  Kijoeng Nam  Ekta Kapadia  Tara Frenkl  Ronald de Wit
Affiliation:1. Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA;2. The University of Texas MD Anderson Cancer Center, Houston, TX, USA;3. University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada;4. University of California Irvine Health, Orange, CA, USA;5. Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands;6. Institut Universitaire du Cancer Toulouse Oncopole CHU, Toulouse, France;7. Genesis Care and Royal North Shore Hospital, Sydney, NSW, Australia;8. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA;9. Memorial Sloan Kettering Cancer Center, New York, NY, USA;10. University of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;11. National Cancer Center, Goyang, South Korea;12. University of Tsukuba, Tsukuba, Ibaraki, Japan;13. University of Minnesota, Minneapolis, MN, USA;14. Merck & Co, Kenilworth, NJ, USA
Abstract:
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号